WO2009079412A3 - Inhibiteurs de transcriptase inverse - Google Patents

Inhibiteurs de transcriptase inverse Download PDF

Info

Publication number
WO2009079412A3
WO2009079412A3 PCT/US2008/086703 US2008086703W WO2009079412A3 WO 2009079412 A3 WO2009079412 A3 WO 2009079412A3 US 2008086703 W US2008086703 W US 2008086703W WO 2009079412 A3 WO2009079412 A3 WO 2009079412A3
Authority
WO
WIPO (PCT)
Prior art keywords
reverse transcriptase
transcriptase inhibitors
inhibitors
hiv
enzyme inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/086703
Other languages
English (en)
Other versions
WO2009079412A2 (fr
Inventor
Aleksandr Shaginian
Samedy Ouk
Jean-Michel Vernier
Anthony B Pinkerton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardea Biociences Inc
Original Assignee
Ardea Biociences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardea Biociences Inc filed Critical Ardea Biociences Inc
Priority to ES08862480T priority Critical patent/ES2389752T3/es
Priority to CA2709176A priority patent/CA2709176C/fr
Priority to EP08862480A priority patent/EP2220091B1/fr
Publication of WO2009079412A2 publication Critical patent/WO2009079412A2/fr
Publication of WO2009079412A3 publication Critical patent/WO2009079412A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des inhibiteurs d'enzyme innovants. Selon certains modes de réalisation, les inhibiteurs d'enzyme sont des inhibiteurs de transcriptase inverse, en particulier des inhibiteurs de la transcriptase inverse du VIH. L'invention concerne également des compositions les contenant et leurs procédés d'utilisation. En conséquence, les composés et les compositions décrits dans la description sont utiles pour l'inhibition in vitro et in vivo de la transcriptase inverse du VIH en tant que procédé de traitement ou de prévention du VIH, du sida ou des affections apparentées.
PCT/US2008/086703 2007-12-14 2008-12-12 Inhibiteurs de transcriptase inverse Ceased WO2009079412A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES08862480T ES2389752T3 (es) 2007-12-14 2008-12-12 Inhibidores de la transcriptasa inversa
CA2709176A CA2709176C (fr) 2007-12-14 2008-12-12 Inhibiteurs de transcriptase inverse
EP08862480A EP2220091B1 (fr) 2007-12-14 2008-12-12 Inhibiteurs de transcriptase inverse

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1398307P 2007-12-14 2007-12-14
US61/013,983 2007-12-14

Publications (2)

Publication Number Publication Date
WO2009079412A2 WO2009079412A2 (fr) 2009-06-25
WO2009079412A3 true WO2009079412A3 (fr) 2009-08-20

Family

ID=40788899

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/086703 Ceased WO2009079412A2 (fr) 2007-12-14 2008-12-12 Inhibiteurs de transcriptase inverse

Country Status (6)

Country Link
US (2) US8207178B2 (fr)
EP (1) EP2220091B1 (fr)
AR (1) AR071739A1 (fr)
CA (1) CA2709176C (fr)
ES (1) ES2389752T3 (fr)
WO (1) WO2009079412A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933227B2 (en) * 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (fr) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Préparation régiosélective de dérivés de 2-amino-5-trifluorométhylpyrimidine
EP2616441B1 (fr) * 2010-09-17 2019-08-07 Purdue Pharma L.P. Composés de pyridine et ses utilisations
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
ES2450944T3 (es) * 2011-06-01 2014-03-25 Ratiopharm Gmbh Composición y comprimido que comprenden raltegravir
US20140315936A1 (en) * 2011-11-18 2014-10-23 Avexa Limited Apricitabine and pi combination therapy
CA2885763C (fr) * 2012-10-23 2021-04-06 Cipla Limited Composition pharmaceutique antiretrovirale
WO2014079545A1 (fr) * 2012-11-20 2014-05-30 Ktb Tumorforschungsgesellschaft Mbh Dérivés de thioéther utilisés en tant qu'inhibiteurs de protéines kinases
US9637493B2 (en) 2012-12-20 2017-05-02 Merck Sharp & Dohme Corp. Substituted pyrrolopyrimidines as HDM2 inhibitors
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
EA201691831A1 (ru) * 2014-04-25 2017-02-28 Пфайзер Инк. Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
EP3134405B1 (fr) 2014-04-25 2019-08-28 Pfizer Inc Composes hetero-aromatiques et leur utilisation comme ligands d1 de la dopamine
US10301624B2 (en) 2014-06-25 2019-05-28 The General Hospital Corporation Targeting human satellite II (HSATII)
AU2016219102B2 (en) 2015-02-13 2020-10-15 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
CN106188060A (zh) * 2015-04-29 2016-12-07 厦门大学 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用
US10729691B2 (en) 2015-06-26 2020-08-04 Kadmon Corporation, Llc Treatment of infectious diseases with glucose uptake inhibitors
CA3028355A1 (fr) * 2015-06-26 2016-12-29 Kadmon Corporation, Llc Inhibiteurs d'absorption du glucose
JP2021512956A (ja) 2018-02-06 2021-05-20 ザ ジェネラル ホスピタル コーポレイション 腫瘍免疫応答のバイオマーカーとしてのリピートｒｎａ
CN109053591A (zh) * 2018-07-04 2018-12-21 复旦大学 含联苯结构的二芳基嘧啶类衍生物及其制备方法和用途
CN110437253A (zh) * 2019-08-06 2019-11-12 复旦大学 含联苯结构的二芳基嘧啶并环化合物及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043394A1 (fr) * 1999-01-26 2000-07-27 Ústav Experimentální Botaniky Av Cr Derives heterocycliques d'azote substitue et leur utilisation pharmaceutique
WO2005028479A2 (fr) * 2003-09-25 2005-03-31 Janssen Pharmaceutica N.V. Derives de purine servant a inhiber la replication du vih
WO2006122003A2 (fr) * 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, -azapurines et -deazapurines inhibiteurs non nucleosidiques de la transcriptase inverse utilises dans le traitement du vih

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1129096B1 (fr) 1998-11-12 2003-05-21 Neurocrine Biosciences, Inc. Antagonistes de recepteurs du crf et methodes associees
WO2000037471A1 (fr) 1998-12-23 2000-06-29 Neurogen Corporation 2-amino-9-alkylpurines: ligands pour recepteurs cerebraux gaba
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
BRPI0407329A (pt) 2003-02-07 2006-01-10 Janssen Pharmaceutica Nv Derivados de pirimidina para a prevenção de infecção de hiv
WO2006009245A1 (fr) 2004-07-23 2006-01-26 Tanabe Seiyaku Co., Ltd. Composé bicyclique azoté
AU2005298637B8 (en) 2004-10-29 2012-12-06 Janssen Sciences Ireland Uc HIV inhibiting bicyclic pyrimidine derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043394A1 (fr) * 1999-01-26 2000-07-27 Ústav Experimentální Botaniky Av Cr Derives heterocycliques d'azote substitue et leur utilisation pharmaceutique
WO2005028479A2 (fr) * 2003-09-25 2005-03-31 Janssen Pharmaceutica N.V. Derives de purine servant a inhiber la replication du vih
WO2006122003A2 (fr) * 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, -azapurines et -deazapurines inhibiteurs non nucleosidiques de la transcriptase inverse utilises dans le traitement du vih

Also Published As

Publication number Publication date
CA2709176A1 (fr) 2009-06-25
ES2389752T3 (es) 2012-10-31
EP2220091B1 (fr) 2012-07-25
US20120277206A1 (en) 2012-11-01
US8207178B2 (en) 2012-06-26
WO2009079412A2 (fr) 2009-06-25
EP2220091A2 (fr) 2010-08-25
EP2220091A4 (fr) 2011-04-27
AR071739A1 (es) 2010-07-14
CA2709176C (fr) 2013-02-05
US20090162319A1 (en) 2009-06-25
US8372852B2 (en) 2013-02-12

Similar Documents

Publication Publication Date Title
WO2009079412A3 (fr) Inhibiteurs de transcriptase inverse
WO2009089263A3 (fr) Nouvelles compositions et procédés d'utilisation
WO2007092622A3 (fr) Compositions et méthodes pour le traitement d'os
MX2009009290A (es) Compuestos activos en ppar.
WO2008073452A8 (fr) Compositions, synthèse et procédés d'utilisation d'inhibiteurs de cholinestérase à base d'indanone
WO2008033562A3 (fr) Composés inhibiteurs de kinases
WO2008128072A3 (fr) Inhibiteurs de la kinase axl
WO2009108383A3 (fr) Dérivés de xanthine substitués
WO2007146965A3 (fr) Composés destinés au traitement d'une maladie périodontale
WO2007104034A3 (fr) Activateurs de la glucokinase
WO2007061923A3 (fr) Activateurs de la glucokinase
WO2007075847A3 (fr) Activateurs de glucokinase
WO2006092213A8 (fr) Pyrazolylcarboxanilides
WO2009026334A3 (fr) Traitement par des inhibiteurs de la kallikréine
WO2007106537A3 (fr) Aminoquinolones utilisées comme inhibiteurs de la gsk-3
WO2008049123A8 (fr) Compositions et procédés pour l'inhibition de la voie jak
WO2009042114A3 (fr) Dérivés de phénazine et leurs utilisations
WO2006073973A3 (fr) Nouveaux dérivés de benzylamine en tant qu'inhibiteurs de cetp
WO2007117995A3 (fr) Inhibiteurs de kinase
WO2008027600A3 (fr) Compositions d'imatinib
ZA201100133B (en) Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
WO2007026251A8 (fr) Utilisation d'inhibiteurs combines c-kit/fgfr3 pour le traitement du myelome multiple
WO2007059230A3 (fr) 1h-benzimidazole-4-carboxamides substitues efficaces en tant qu’inhibiteurs de parp
WO2008061108A3 (fr) Dérivés de phtalazine
WO2009035634A3 (fr) Cyanoaminoquinolones et tétrazoloaminoquinolones en tant qu'inhibiteurs de gsk-3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08862480

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2709176

Country of ref document: CA

Ref document number: 2008862480

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE